EyePoint Positive 6-Month Results for Phase 2 Trial for Diabetic Macular Edema

 

Meeting Primary and Secondary Endpoints

 Primary endpoint achieved by both DURAVYU doses (1.34mg and 2.7mg) with extended time to first supplemental injection versus aflibercept control –

- DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a 24-week gain of +7.1 letters and anatomical improvement of 76 microns reduction in CST paired with reduction in treatment burden of two-thirds

– Favorable safety profile continues with no DURAVYU-related ocular or systemic SAEs –

– Phase 3 non-inferiority pivotal program initiation anticipated by the end of 2025 –

https://www.globenewswire.com/news-release/2025/02/05/3021051/0/en/EyePoint-Announces-Positive-Six-Month-Results-for-the-Phase-2-VERONA-Clinical-Trial-of-DURAVYU-for-Diabetic-Macular-Edema-Meeting-Primary-and-Secondary-Endpoints.html